|
|
 |
|
Viewing report
|
|
|
|
Pfizer Inc.: PharmaVitae Profile
Datamonitor, Nov 2010, Pages: 122
Introduction
This analysis examines the historical and forecast performance for Pfizer in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Pfizer's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Pfizer over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Pfizer's performance against key rivals in the prescription pharmaceutical sector
- Assess how large scale M&A has shaped Pfizer's growth over the previous decade and how the Wyeth acquisition will impact growth through to 2015.
- Analyse how the sustainability of Pfizer’s blockbuster model will come under significant pressure when Lipitor loses US patent exclusivity in mid-2011
|
|
|
|
